1. The combination therapy of Everolimus and anti-PD-1 improves the antitumor effect by regulating CD8⁺ T cells in bladder cancer

   • Weimin Xia
   • Shun Zhang
   • Haibo Shen

   Original Paper 20 January 2022 Article: 37

   

2. SOX2 knockdown with siRNA reverses cisplatin resistance in NSCLC by regulating APE1 signaling

   • Tai-yu Chen
   • Ji Zhou
   • Tao Ren

   Original Paper Open access 20 January 2022 Article: 36

   

3. Resveratrol triggers anti-proliferative and apoptotic effects in FLT3-ITD-positive acute myeloid leukemia cells via inhibiting ceramide catabolism enzymes

   • Nur Şebnem Ersöz
   • Aysun Adan

   Original Paper 20 January 2022 Article: 35

   

4. DNA damage induced cellular senescence and it’s PTEN-armed exosomes—the warriors against prostate carcinoma cells

   • Sougata Ghosh Chowdhury
   • Rachayeeta Ray
   • Parimal Karmakar

   Original Paper 20 January 2022 Article: 34

   

5. Who should be treated with pembrolizumab in addition to standard of care in advanced cervical cancer?

   • Seda Kahraman
   • Ulviye Esra Erbas
   • Bulent Yalcin

   Letter to the Editor 20 January 2022 Article: 33

6. SARS-CoV-2 spike protein inhibits growth of prostate cancer: a potential role of the COVID-19 vaccine killing two birds with one stone

   • Bradley D. Johnson
   • Ziwen Zhu
   • Yujiang Fang

   Original Paper 20 January 2022 Article: 32

   

7. Bioinformatics analysis of recurrent deletion regions in neuroblastoma

   • Hasan Onur Caglar

   Original Paper 20 January 2022 Article: 31

   

8. Critical pathways of oral squamous cell carcinoma: molecular biomarker and therapeutic intervention

   • Sharmistha Dey
   • Abhay Kumar Singh
   • Deepak Upadhaya

   Review Article 20 January 2022 Article: 30

   

9. Comparative expression analysis of dasatinib and ponatinib-regulated lncRNAs in chronic myeloid leukemia and their network analysis

   • Cagla Kayabasi
   • Ayse Caner
   • Cumhur Gunduz

   Original Paper 20 January 2022 Article: 29

   

10. The inhibition of Panc1 cancer cells invasion by hAMSCs secretome through suppression of tyrosine phosphorylation of SGK223 (at Y411 site), c-Src (at Y416, Y530 sites), AKT activity, and JAK1/Stat3 signaling

    • Fatemeh Safari
    • Nasim Shafiee Nejad
    • Azadeh Aghaei Nejad

    Original Paper 20 January 2022 Article: 28